Our results suggest that the overexpression of CBX3 promotes ccRCC advancement through PI3K/AKT activation and even immunological dysregulation, making it a potentially viable and beneficial therapeutic target. The gene discussed is PIK3CA; the disease is nonpapillary renal cell carcinoma.